Neogen Corporation (NEOG)
NEOG Stock Price Chart
Explore Neogen Corporation interactive price chart. Choose custom timeframes to analyze NEOG price movements and trends.
NEOG Company Profile
Discover essential business fundamentals and corporate details for Neogen Corporation (NEOG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
23 Aug 1989
Employees
2.92k
Website
https://www.neogen.comCEO
Mikhael Nassif
Description
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
NEOG Financial Timeline
Browse a chronological timeline of Neogen Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.05, while revenue estimate is $212.35m.
Earnings released on 9 Apr 2026
EPS came in at $0.09 surpassing the estimated $0.04 by +125.00%, while revenue for the quarter reached $211.20m , beating expectations by +3.28%.
Earnings released on 8 Jan 2026
EPS came in at $0.10 surpassing the estimated $0.07 by +42.86%, while revenue for the quarter reached $224.69m , beating expectations by +8.18%.
Earnings released on 9 Oct 2025
EPS came in at $0.04 surpassing the estimated -$0.07 by +154.05%, while revenue for the quarter reached $209.19m , beating expectations by +3.00%.
Earnings released on 29 Jul 2025
EPS came in at $0.05 falling short of the estimated $0.08 by -37.50%, while revenue for the quarter reached $225.46m , beating expectations by +11.25%.
Earnings released on 9 Apr 2025
EPS came in at $0.10 falling short of the estimated $0.13 by -23.08%, while revenue for the quarter reached $220.98m , missing expectations by -0.70%.
Earnings released on 10 Jan 2025
EPS came in at $0.11 surpassing the estimated $0.09 by +22.22%, while revenue for the quarter reached $231.26m , beating expectations by +1.40%.
Earnings released on 10 Oct 2024
EPS came in at $0.07 falling short of the estimated $0.09 by -17.65%, while revenue for the quarter reached $216.96m , beating expectations by +0.89%.
Earnings released on 30 Jul 2024
EPS came in at $0.10 falling short of the estimated $0.12 by -16.67%, while revenue for the quarter reached $236.79m , beating expectations by +4.85%.
Earnings released on 9 Apr 2024
EPS came in at $0.12 falling short of the estimated $0.14 by -14.29%, while revenue for the quarter reached $228.81m , missing expectations by -2.94%.
Earnings released on 9 Jan 2024
EPS came in at $0.11 falling short of the estimated $0.15 by -26.67%, while revenue for the quarter reached $229.63m , missing expectations by -1.39%.
Earnings released on 10 Oct 2023
EPS came in at $0.11 falling short of the estimated $0.14 by -21.43%, while revenue for the quarter reached $228.99m , missing expectations by -0.91%.
Earnings released on 27 Jul 2023
EPS came in at $0.14 surpassing the estimated $0.10 by +40.00%, while revenue for the quarter reached $241.81m , beating expectations by +6.22%.
Earnings released on 30 Mar 2023
EPS came in at $0.12 surpassing the estimated $0.03 by +366.74%, while revenue for the quarter reached $218.26m , missing expectations by -0.28%.
Earnings released on 5 Jan 2023
EPS came in at $0.15 surpassing the estimated -$0.08 by +287.50%, while revenue for the quarter reached $230.03m , beating expectations by +0.76%.
Earnings released on 27 Sept 2022
EPS came in at $0.15 falling short of the estimated $0.16 by -6.25%, while revenue for the quarter reached $132.35m , missing expectations by -2.51%.
Earnings released on 26 Jul 2022
EPS came in at $0.14 surpassing the estimated $0.12 by +16.67%, while revenue for the quarter reached $140.09m , beating expectations by +1.25%.
Earnings released on 24 Mar 2022
EPS came in at $0.13 falling short of the estimated $0.15 by -13.33%, while revenue for the quarter reached $128.24m , missing expectations by -1.35%.
Earnings released on 21 Dec 2021
EPS came in at $0.17 matching the estimated $0.17, while revenue for the quarter reached $130.52m , beating expectations by +0.41%.
Earnings released on 21 Sept 2021
EPS came in at $0.16 matching the estimated $0.16, while revenue for the quarter reached $128.31m , beating expectations by +7.14%.
Earnings released on 20 Jul 2021
EPS came in at $0.15 falling short of the estimated $0.17 by -11.76%, while revenue for the quarter reached $127.43m , beating expectations by +5.14%.
NEOG Stock Performance
Access detailed NEOG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
